NIH Funding Opportunities

Subscribe to NIH Funding Opportunities feed
Weekly Funding Opportunities and Policy Notices from the National Institutes of Health.
Updated: 1 hour 21 min ago

Revision Applications to Support the Application of Informatics Technology for Cancer Research (U01 Clinical Trials Optional)

Wed, 07/31/2019 - 09:02
Funding Opportunity RFA-CA-19-061 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U01 research projects proposing to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating informatics methods, tools or resources developed through current or previous support from the NCI Informatics Technology for Cancer Research (ITCR) Program. Awards from this FOA are meant to spur novel collaborations and to incentivize the adoption, adaptation, and integration of these informatics technologies in support of the appropriate research communities. As a component of the NCI ITCR program, this FOA aims to promote interdisciplinary collaboration in the adoption and enhancement of innovative informatics methods, tools, and resources that enable cancer research and accelerate scientific discovery.
Categories: Science RSS Feeds

US Children with Perinatal HIV who were Born Internationally (R01 Clinical Trial Optional)

Wed, 07/31/2019 - 07:48
Funding Opportunity RFA-HD-20-006 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to stimulate research on an area of emerging public health significance and improve understanding of the natural history, epidemiology, diagnosis and management of HIV and co-morbid conditions among US children who were born internationally and acquired HIV from their mothers.
Categories: Science RSS Feeds

Palliative Care in Home and Community Settings (R01 Clinical Trial Optional)

Wed, 07/31/2019 - 07:34
Funding Opportunity PAR-19-321 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity is to stimulate research aimed at determining needs and best practices for the integration of palliative care into home and community settings. Home and community in this FOA refer to the place where an individual resides or lives. Home- and community-based palliative care programs ensure those with serious, advanced illness who do not require hospitalization but are not appropriate for hospice have access to high quality end-of-life and palliative care.
Categories: Science RSS Feeds

Palliative Care in Home and Community Settings (R21 Clinical Trial Optional)

Wed, 07/31/2019 - 07:32
Funding Opportunity PAR-19-320 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity is to stimulate research aimed at determining needs and best practices for the integration of palliative care into home and community settings. Home and community in this FOA refer to the place where an individual resides or lives. Home- and community-based palliative care programs ensure those with serious, advanced illness who do not require hospitalization but are not appropriate for hospice have access to high quality end-of-life and palliative care.
Categories: Science RSS Feeds

Participant Engagement and Cancer Genome Sequencing (PE-CGS): Research Centers (U2C Clinical Trial Optional)

Tue, 07/30/2019 - 11:47
Funding Opportunity RFA-CA-19-045 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSMInitiative that is intended to accelerate cancer research. Specifically, this FOA falls under a scientific priority designated by the Blue Ribbon Panel (BRP) as Recommendation A "Establish a Network for Direct Patient Engagement". The National Cancer Institute (NCI) intends to support the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network. The PE-CGS Network will include: Several U2C Research Centers (to be supported under this FOA); and One U24 Coordinating Center (to be supported under companion RFA-CA-19-046). The overall purpose of the PE-CGS Network is twofold: To promote and support research on direct participant* engagement approaches; and Use such approaches for rigorous cancer genome sequencing projects addressing important knowledge gaps in the genomic characterizations of tumors in areas such as, but not limited to: Rare cancers or rare cancer subsets; Highly lethal cancers; Cancers with an early age of onset; Cancers with high disparities in incidence and/or mortality; or Cancers in understudied populations. *Note: For this FOA, study participant denotes cancer patients and/or post-treatment cancer survivors. Each PE-CGS U2C Research Center to be proposed in response to this FOA must consist of the following components: Administrative Core Participant Engagement Unit; Genome Characterization Unit; and Engagement Optimization Unit. In addition to conducting individual projects, PE-CGS U2C Research Centers will be expected to operate as a collaborative network. Various trans-network activities will be facilitated by the PE-CGS Network Coordinating Center (U24).
Categories: Science RSS Feeds

Participant Engagement and Cancer Genome Sequencing (PE-CGS): Coordinating Center (U24 Clinical Trial Not Allowed)

Tue, 07/30/2019 - 11:47
Funding Opportunity RFA-CA-19-046 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSMInitiative that is intended to accelerate cancer research. Specifically, this FOA falls under a scientific priority designated by the Blue Ribbon Panel (BRP) as Recommendation A "Establish a Network for Direct Patient Engagement". The National Cancer Institute (NCI) intends to support the Participant Engagement and Cancer Genome Sequencing (PE-CGS) Network. The PE-CGS Network will include: Several U2C Research Centers (to be supported under companion RFA-CA-19-045); and One U24 Coordinating Center (to be supported under this FOA). The overall purpose of the PE-CGS Network is twofold: To promote and support research on direct participant* engagement approaches; and Use such approaches for rigorous cancer genome sequencing projects addressing important knowledge gaps in the genomic characterizations of tumors in areas such as, but not limited to: Rare cancers or rare cancer subsets; Highly lethal cancers; Cancers with an early age of onset; Cancers with high disparities in incidence and/or mortality; or Cancers in understudied populations. *Note: For this FOA, study participant denotes cancer patients and/or post-treatment cancer survivors. PE-CGS U2C Research Centers, together with the PE-CGS U24 Coordinating Center, will form a collaborative Network. The PE-CGS U24 Coordinating Center will have three major areas of responsibility: (1) Network Coordination; (2) Network Outreach and Promotion; and (3) Network Best Practices.
Categories: Science RSS Feeds

Notice of Change to PAR-18-581 "Emotional Function in Normal Aging and/or MCI and AD/ADRD (R01 Clinical Trial Optional)"

Tue, 07/30/2019 - 11:30
Notice NOT-AG-19-026 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

Notice of Change to PAR-18-582 "Emotional Function in Normal Aging and/or MCI and AD/ADRD (R21 Clinical Trial Not Allowed)"

Tue, 07/30/2019 - 11:20
Notice NOT-AG-19-025 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

The Role of Stem/Progenitor Cells in the Pathogenesis and Treatment of Gynecologic Disorders (R21 Clinical Trial Optional)

Tue, 07/30/2019 - 11:03
Funding Opportunity RFA-HD-20-007 from the NIH Guide for Grants and Contracts. The primary focus of this FOA is to promote studies which apply state-of-the art concepts, technologies, and methodologies in the stem cell field to better understand how stem cells function within diseased or damaged gynecologic tissues. For the purposes of this announcement, the gynecologic disorders of interest are limited to uterine fibroids, endometriosis, adenomyosis, endometrial polyps, and pelvic organ prolapse. These disorders have been chosen based on their prevalence, high associated morbidity, high branch priority, and substantial costs to the healthcare system. The ultimate goal of this initiative is to improve womens gynecologic health by accelerating our understanding of the role of pluripotent progenitor/stem cells in the initiation, progression and severity of these gynecologic disorders in order to inform the development of effective prevention, diagnostic, and therapeutic strategies.
Categories: Science RSS Feeds

Fast Healthcare Interoperability Resources (FHIR) Standard

Tue, 07/30/2019 - 11:00
Notice NOT-OD-19-122 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

Notice of Correction to RFA-RM-19-008 NIH Directors Early Independence Awards (DP5 Clinical Trial Optional)

Tue, 07/30/2019 - 10:26
Notice NOT-RM-19-013 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

Revised NIAID Policy for T32 and T35 Competing Renewal Application Submissions

Tue, 07/30/2019 - 10:21
Notice NOT-AI-19-064 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)

Tue, 07/30/2019 - 00:10
Funding Opportunity PAR-19-325 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.
Categories: Science RSS Feeds

NOTICE OF INFORMATION: NIGMS Priorities for Sepsis Research

Mon, 07/29/2019 - 11:51
Notice NOT-GM-19-054 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

Request for Information (RFI): Precision Nutrition Tools for Continuous Monitoring of Nutrients and Metabolites in Humans

Mon, 07/29/2019 - 09:50
Notice NOT-DK-19-021 from the NIH Guide for Grants and Contracts
Categories: Science RSS Feeds

Pages